Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pocenbrodib |
Synonyms | |
Therapy Description |
FT-7051 inhibits CREB binding protein (CBP) and p300, which may lead to anti-tumor activities (PMID: 33785255). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pocenbrodib | FT7051|FT 7051|FT7-051 | CBP/p300 inhibitor 13 | Pocenbrodib inhibits CREB binding protein (CBP) and p300, which potentially decreases proliferation of tumor cells expressing AR (Blood Cancer Discov (2024) 5 (2_Supplement): P33, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04575766 | Phase I | Pocenbrodib | A Study of FT-7051 in Men With MCRPC | Terminated | USA | 0 |
NCT06785636 | Phase Ib/II | Pocenbrodib Abiraterone + Pocenbrodib Olaparib + Pocenbrodib lutetium Lu 177 vipivotide tetraxetan + Pocenbrodib | Open-Label Study of Pocenbrodib and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 (P300) | Recruiting | USA | 0 |